Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Regulus Therapeutics has granted Sanofi an exclusive license for RG-012, a microRNA therapeutic in a Phase II study for a genetic kidney disease called Alport syndrome. Running low on cash, Regulus in July laid off 60% of its staff and paused recruitment for the RG-012 trial while it reconfigured its long-standing partnership with Sanofi. The French drug firm will pay roughly $7 million for full rights to RG-012 and reimburse Regulus for some activities.
This article has been sent to the following recipient: